Rubius Therapeutics has pulled in another $100 million to fund the advance of its red blood cell therapies. The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the ...

In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...

Rubius Therapeutics’ plan to revive its red blood cell therapy research with a new approach has run out of time and money, and the biotech is now looking to strike a deal to salvage what’s left of the ...

Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — ...

Investors are always looking for stocks that are poised to beat at earnings season and Rubius Therapeutics, Inc. RUBY may be one such company. The firm has earnings coming up pretty soon, and events ...

After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...

It’s the end of the road for Rubius Therapeutics, a biotech that previously wanted to develop cellular therapies for rare diseases, cancer and autoimmune diseases. After a last-ditch effort last year ...